TRANSCRIPTIONAL AND POSTTRANSCRIPTIONAL REGULATION OF THE RECEPTOR FOR UROKINASE-TYPE PLASMINOGEN-ACTIVATOR BY CYTOKINES AND TUMOR PROMOTERS IN THE HUMAN LUNG-CARCINOMA CELL-LINE A549

被引:110
作者
LUND, LR
ELLIS, V
RONNE, E
PYKE, C
DANO, K
机构
[1] RIGSHOSP, FINSEN LAB, DK-2100 COPENHAGEN, DENMARK
[2] THROMBOSIS RES INST, LONDON SW3 6LR, ENGLAND
关键词
D O I
10.1042/bj3100345
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The receptor for urokinase-type plasminogen activator (uPAR) is an integral membrane protein that specifically binds urokinase-type plasminogen activator (uPA) and plays a crucial role in cell surface plasmin generation. We have previously found that transforming growth factor-beta, type 1 (TGF-beta 1), increases uPAR gene transcription in the human lung carcinoma cell line A549 and now report that also epidermal growth factor (EGF) and the tumour promoter phorbol 12-myristate 13-acetate (PMA) cause increased uPAR transcription and that PMA and TGF-beta 1 in addition increase the stability of uPAR mRNA, while EGF has no effect on this parameter. All three compounds also increase the uPAR protein level, as measured by cell-binding experiments with radiolabelled ligand. The increase in uPAR protein level was however considerably lower with all three compounds than the increase in mRNA level, suggesting that they also exert a translational or post-translational control. Accompanying the increase in the number of uPAR molecules there was a proportional decrease in their ligand-binding affinity, the mechanism of which is unknown. Platelet-derived growth factor, basic fibroblast growth factor and cyclic AMP analogues did not induce any change in the uPAR mRNA level in A549 cells. Previous studies have shown that expression of uPA and its type-1 inhibitor is regulated by a variety of cytokines in a cell-specific manner. The present study indicates that cytokines in addition influence cell surface plasminogen activation by regulating uPAR expression.
引用
收藏
页码:345 / 352
页数:8
相关论文
共 47 条
  • [1] AKIYAMA T, 1987, J BIOL CHEM, V262, P5592
  • [2] PLASMINOGEN-ACTIVATOR INHIBITORS - HORMONALLY REGULATED SERPINS
    ANDREASEN, PA
    GEORG, B
    LUND, LR
    RICCIO, A
    STACEY, SN
    [J]. MOLECULAR AND CELLULAR ENDOCRINOLOGY, 1990, 68 (01) : 1 - 19
  • [3] BEHRENDT N, 1991, J BIOL CHEM, V266, P7842
  • [4] BEHRENDT N, 1990, J BIOL CHEM, V265, P6453
  • [5] BORGLUM AD, 1992, AM J HUM GENET, V50, P492
  • [6] BOYD D, 1989, CANCER RES, V49, P2427
  • [7] CARPENTER G, 1990, J BIOL CHEM, V265, P7709
  • [8] THE UROKINASE RECEPTOR - PROTEIN-STRUCTURE AND ROLE IN PLASMINOGEN ACTIVATION AND CANCER INVASION
    DANO, K
    BEHRENDT, N
    BRUNNER, N
    ELLIS, V
    PLOUG, M
    PYKE, C
    [J]. FIBRINOLYSIS, 1994, 8 : 189 - 203
  • [9] PLASMINOGEN ACTIVATORS, TISSUE DEGRADATION, AND CANCER
    DANO, K
    ANDREASEN, PA
    GRONDAHLHANSEN, J
    KRISTENSEN, P
    NIELSEN, LS
    SKRIVER, L
    [J]. ADVANCES IN CANCER RESEARCH, 1985, 44 : 139 - 266
  • [10] HUMAN TRANSFORMING GROWTH FACTOR-BETA COMPLEMENTARY-DNA SEQUENCE AND EXPRESSION IN NORMAL AND TRANSFORMED-CELLS
    DERYNCK, R
    JARRETT, JA
    CHEN, EY
    EATON, DH
    BELL, JR
    ASSOIAN, RK
    ROBERTS, AB
    SPORN, MB
    GOEDDEL, DV
    [J]. NATURE, 1985, 316 (6030) : 701 - 705